3 US Penny Stocks With Market Caps Under $200M

The U.S. stock market has been experiencing fluctuations, with the S&P 500 recently reaching record highs while futures indicate a slightly lower open. Penny stocks, though an older term, still capture interest due to their potential for growth at accessible price points. These stocks often represent smaller or newer companies and can offer intriguing opportunities when backed by strong financials and fundamentals.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
QuantaSing Group (NasdaqGM:QSG)	$3.08	$130.85M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.82	$84.63M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.45	$47.85M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.2601	$9.93M	★★★★★★
PHX Minerals (NYSE:PHX)	$4.18	$153.67M	★★★★★☆
Smith Micro Software (NasdaqCM:SMSI)	$1.40	$25.9M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.889	$80.05M	★★★★★☆
BAB (OTCPK:BABB)	$0.86825	$6.26M	★★★★★☆
Lifetime Brands (NasdaqGS:LCUT)	$5.00	$114.11M	★★★★★☆

Click here to see the full list of 708 stocks from our US Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Kyverna Therapeutics (NasdaqGS:KYTX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of cell therapies for autoimmune diseases, with a market cap of $128.22 million.

Operations: Kyverna Therapeutics, Inc. has not reported any revenue segments.

Market Cap: $128.22M

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company with a market cap of US$128.22 million, is pre-revenue and currently unprofitable. Despite its financial challenges, Kyverna benefits from being debt-free and having sufficient cash runway for over three years based on current free cash flow levels. However, the company's stock exhibits high volatility and faces legal challenges including securities class action lawsuits related to its February 2024 IPO. Recent executive changes include the appointment of Dr. Naji Gehchan as Chief Medical and Development Officer to strengthen leadership in research and clinical development efforts amidst ongoing strategic shifts.

• Take a closer look at Kyverna Therapeutics' potential here in our financial health report.
• Gain insights into Kyverna Therapeutics' future direction by reviewing our growth report.

PetMed Express (NasdaqGS:PETS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: PetMed Express, Inc., along with its subsidiaries, operates as a pet pharmacy in the United States and has a market cap of $92.41 million.

Operations: The company's revenue segment includes $247.01 million from online retailers.

Market Cap: $92.41M

PetMed Express, Inc., with a market cap of US$92.41 million, has recently become profitable but faces challenges with declining earnings forecasted to drop by an average of 51.2% annually over the next three years. The company is debt-free and its short-term assets exceed both short- and long-term liabilities, providing some financial stability. However, its share price remains highly volatile and recent results show a decrease in sales to US$52.98 million for Q3 compared to US$65.32 million the previous year, though net losses have narrowed significantly from US$2.03 million to US$0.707 million over the same period.

• Navigate through the intricacies of PetMed Express with our comprehensive balance sheet health report here.
• Review our growth performance report to gain insights into PetMed Express' future.

2seventy bio (NasdaqGS:TSVT)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: 2seventy bio, Inc. is a cell and gene therapy company dedicated to researching, developing, and commercializing cancer treatments in the United States, with a market cap of $123.30 million.

Operations: The company generates revenue from its biotechnology segment, amounting to $45.62 million.

Market Cap: $123.3M

2seventy bio, Inc., with a market cap of US$123.30 million, is navigating the challenging landscape of biotechnology as an unprofitable entity but has reduced its losses by 12.3% annually over the past five years. Its short-term assets of US$218.5 million comfortably cover its short-term liabilities of US$44.1 million, although long-term liabilities remain uncovered at US$231.6 million. The company benefits from a cash runway exceeding one year and remains debt-free, yet faces high share price volatility and significant insider selling recently. Leadership changes include Jessica Snow's promotion to Chief Operating Officer in January 2025 amidst management inexperience concerns.

• Click to explore a detailed breakdown of our findings in 2seventy bio's financial health report.
• Explore 2seventy bio's analyst forecasts in our growth report.

Turning Ideas Into Actions

• Unlock more gems! Our US Penny Stocks screener has unearthed 705 more companies for you to explore.Click here to unveil our expertly curated list of 708 US Penny Stocks.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com